Log In

Fibroblast Activation Protein Inhibitor-PET Imaging in Colorectal Cancer

Files

1_s2.0_S1556859823000160_main.pdf (789.63 KB)

Publication date

2023-07

Authors

Strating, Esther A
van de Loo, Anne
Elias, S. G.ISNI 0000000388198607
G. E. H. Lam, MarnixORCID 0000-0002-4902-9790
Kranenburg, OnnoORCID 0000-0002-2112-4390ISNI 0000000395167454

Editors

Advisors

Supervisors

DOI

https://doi.org/10.1016/j.cpet.2023.02.003

Document Type

Article

Metadata

Show full item record

Collections

UMC Repository
Open Access logo

License

taverne

Abstract

Fibroblast activation protein inhibitor (FAPI)-PET imaging holds great promise for improving the clinical management of colorectal cancer. High fibroblast activation protein expression is particularly observed in lymph node metastases, in the aggressive Consensus Molecular Subtype 4, in peritoneal metastases, and in tumors that respond poorly to immunotherapy. We have defined six clinical dilemmas in the diagnosis and treatment of colorectal cancer, which FAPI-PET may help solve. Future clinical trials should include patients undergoing tumor resection, allowing correlation of FAPI-PET signals with in-depth histopathological, cellular, and molecular tissue analyses.

Keywords

Colorectal cancer, Fibroblast activation protein, Fibroblast activation protein inhibitor, Peritoneal metastases, PET, Taverne, Radiation, Radiology Nuclear Medicine and imaging, Review, Journal Article

Citation

Strating, E, van de Loo, A, Elias, S, Lam, M & Kranenburg, O 2023, 'Fibroblast Activation Protein Inhibitor-PET Imaging in Colorectal Cancer', PET Clinics, vol. 18, no. 3, pp. 325-335. https://doi.org/10.1016/j.cpet.2023.02.003

URI

http://hdl.handle.net/1874/449224